Logo image of IS7.DE

INTICA SYSTEMS SE (IS7.DE) Stock Fundamental Analysis

Europe - FRA:IS7 - DE0005874846 - Common Stock

2.07 EUR
-0.02 (-0.96%)
Last: 9/24/2025, 7:00:00 PM
Fundamental Rating

3

IS7 gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 53 industry peers in the Electronic Equipment, Instruments & Components industry. Both the profitability and financial health of IS7 have multiple concerns. IS7 does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

2

1. Profitability

1.1 Basic Checks

IS7 had negative earnings in the past year.
IS7 had a positive operating cash flow in the past year.
The reported net income has been mixed in the past 5 years: IS7 reported negative net income in multiple years.
In the past 5 years IS7 always reported a positive cash flow from operatings.
IS7.DE Yearly Net Income VS EBIT VS OCF VS FCFIS7.DE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5M -5M

1.2 Ratios

Looking at the Return On Assets, with a value of -7.00%, IS7 is doing worse than 73.58% of the companies in the same industry.
IS7 has a Return On Equity of -24.64%. This is in the lower half of the industry: IS7 underperforms 69.81% of its industry peers.
Industry RankSector Rank
ROA -7%
ROE -24.64%
ROIC N/A
ROA(3y)-1.02%
ROA(5y)0.02%
ROE(3y)-3.67%
ROE(5y)-0.35%
ROIC(3y)N/A
ROIC(5y)N/A
IS7.DE Yearly ROA, ROE, ROICIS7.DE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5 -5 -10

1.3 Margins

IS7's Operating Margin has declined in the last couple of years.
With a Gross Margin value of 43.37%, IS7 perfoms like the industry average, outperforming 58.49% of the companies in the same industry.
In the last couple of years the Gross Margin of IS7 has remained more or less at the same level.
IS7 does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 43.37%
OM growth 3Y-45.56%
OM growth 5Y-27.46%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y5.66%
GM growth 5Y1.46%
IS7.DE Yearly Profit, Operating, Gross MarginsIS7.DE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10 20 30 40

3

2. Health

2.1 Basic Checks

IS7 does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for IS7 remains at a similar level compared to 1 year ago.
Compared to 5 years ago, IS7 has about the same amount of shares outstanding.
Compared to 1 year ago, IS7 has a worse debt to assets ratio.
IS7.DE Yearly Shares OutstandingIS7.DE Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 1M 2M 3M 4M
IS7.DE Yearly Total Debt VS Total AssetsIS7.DE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M

2.2 Solvency

Based on the Altman-Z score of 0.99, we must say that IS7 is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of 0.99, IS7 is doing worse than 79.25% of the companies in the same industry.
IS7 has a debt to FCF ratio of 3.86. This is a good value and a sign of high solvency as IS7 would need 3.86 years to pay back of all of its debts.
IS7 has a Debt to FCF ratio of 3.86. This is in the better half of the industry: IS7 outperforms 64.15% of its industry peers.
A Debt/Equity ratio of 0.34 indicates that IS7 is not too dependend on debt financing.
IS7 has a Debt to Equity ratio (0.34) which is comparable to the rest of the industry.
Industry RankSector Rank
Debt/Equity 0.34
Debt/FCF 3.86
Altman-Z 0.99
ROIC/WACCN/A
WACC6.06%
IS7.DE Yearly LT Debt VS Equity VS FCFIS7.DE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5M -5M 10M 15M 20M

2.3 Liquidity

IS7 has a Current Ratio of 0.84. This is a bad value and indicates that IS7 is not financially healthy enough and could expect problems in meeting its short term obligations.
IS7 has a worse Current ratio (0.84) than 88.68% of its industry peers.
IS7 has a Quick Ratio of 0.84. This is a bad value and indicates that IS7 is not financially healthy enough and could expect problems in meeting its short term obligations.
IS7's Quick ratio of 0.42 is on the low side compared to the rest of the industry. IS7 is outperformed by 88.68% of its industry peers.
Industry RankSector Rank
Current Ratio 0.84
Quick Ratio 0.42
IS7.DE Yearly Current Assets VS Current LiabilitesIS7.DE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M

3

3. Growth

3.1 Past

The earnings per share for IS7 have decreased strongly by -178.66% in the last year.
The Revenue for IS7 has decreased by -18.91% in the past year. This is quite bad
IS7 shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 1.44% yearly.
EPS 1Y (TTM)-178.66%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-200%
Revenue 1Y (TTM)-18.91%
Revenue growth 3Y-9.65%
Revenue growth 5Y1.44%
Sales Q2Q%-10.33%

3.2 Future

Based on estimates for the next years, IS7 will show a very strong growth in Earnings Per Share. The EPS will grow by 36.68% on average per year.
Based on estimates for the next years, IS7 will show a small growth in Revenue. The Revenue will grow by 3.82% on average per year.
EPS Next Y25%
EPS Next 2Y36.93%
EPS Next 3Y36.68%
EPS Next 5YN/A
Revenue Next Year-2.27%
Revenue Next 2Y1.76%
Revenue Next 3Y3.82%
Revenue Next 5YN/A

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
IS7.DE Yearly Revenue VS EstimatesIS7.DE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 20M 40M 60M 80M
IS7.DE Yearly EPS VS EstimatesIS7.DE Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 0 0.2 -0.2 0.4 -0.4

3

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for IS7. In the last year negative earnings were reported.
Also next year IS7 is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
IS7.DE Price Earnings VS Forward Price EarningsIS7.DE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 -10 20 -20

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, IS7 is valued a bit cheaper than the industry average as 66.04% of the companies are valued more expensively.
Based on the Price/Free Cash Flow ratio, IS7 is valued cheaply inside the industry as 98.11% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF 1.3
EV/EBITDA 7.48
IS7.DE Per share dataIS7.DE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10 15

4.3 Compensation for Growth

A more expensive valuation may be justified as IS7's earnings are expected to grow with 36.68% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y36.93%
EPS Next 3Y36.68%

0

5. Dividend

5.1 Amount

IS7 does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

INTICA SYSTEMS SE

FRA:IS7 (9/24/2025, 7:00:00 PM)

2.07

-0.02 (-0.96%)

Chartmill FA Rating
GICS IndustryGroupTechnology Hardware & Equipment
GICS IndustryElectronic Equipment, Instruments & Components
Earnings (Last)08-08 2025-08-08
Earnings (Next)11-25 2025-11-25
Inst OwnersN/A
Inst Owner ChangeN/A
Ins Owners60.42%
Ins Owner ChangeN/A
Market Cap8.88M
Analysts45.71
Price Target3.67 (77.29%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-5.26%
PT rev (3m)-18.18%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)-31.25%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)-6.5%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.14
P/FCF 1.3
P/OCF 0.98
P/B 0.56
P/tB 0.8
EV/EBITDA 7.48
EPS(TTM)-0.94
EYN/A
EPS(NY)-0.07
Fwd EYN/A
FCF(TTM)1.59
FCFY76.71%
OCF(TTM)2.11
OCFY102.03%
SpS15.3
BVpS3.72
TBVpS2.58
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -7%
ROE -24.64%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 43.37%
FCFM 10.38%
ROA(3y)-1.02%
ROA(5y)0.02%
ROE(3y)-3.67%
ROE(5y)-0.35%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)1.7%
ROCE(5y)3.73%
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3Y-45.56%
OM growth 5Y-27.46%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y5.66%
GM growth 5Y1.46%
F-Score4
Asset Turnover1.17
Health
Industry RankSector Rank
Debt/Equity 0.34
Debt/FCF 3.86
Debt/EBITDA 1.26
Cap/Depr 34.08%
Cap/Sales 3.43%
Interest Coverage N/A
Cash Conversion 211.31%
Profit Quality N/A
Current Ratio 0.84
Quick Ratio 0.42
Altman-Z 0.99
F-Score4
WACC6.06%
ROIC/WACCN/A
Cap/Depr(3y)103.63%
Cap/Depr(5y)82.04%
Cap/Sales(3y)7.51%
Cap/Sales(5y)5.88%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-178.66%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-200%
EPS Next Y25%
EPS Next 2Y36.93%
EPS Next 3Y36.68%
EPS Next 5YN/A
Revenue 1Y (TTM)-18.91%
Revenue growth 3Y-9.65%
Revenue growth 5Y1.44%
Sales Q2Q%-10.33%
Revenue Next Year-2.27%
Revenue Next 2Y1.76%
Revenue Next 3Y3.82%
Revenue Next 5YN/A
EBIT growth 1Y-992.66%
EBIT growth 3Y-50.82%
EBIT growth 5Y-26.41%
EBIT Next Year1216.67%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y269.96%
FCF growth 3YN/A
FCF growth 5Y-9.62%
OCF growth 1Y43.35%
OCF growth 3Y29.25%
OCF growth 5Y-6.33%